Fed. Circ. Denies Eon's Fee Bid In Skelaxin IP Case

Law360, New York (August 12, 2011, 8:28 PM EDT) -- Having last year affirmed the invalidity of two patents for the muscle relaxant Skelaxin that King Pharmaceuticals Inc. asserted against Eon Labs Inc., the Federal Circuit ruled Friday that the case was not exceptional and Eon was not entitled to attorneys' fees.

King sued Eon in 2004, alleging that Eon's proposed generic version of Skelaxin would infringe two of its patents. Eon argued that the case was exceptional because King and its predecessors had committed inequitable conduct before the U.S. Patent and Trademark Office, but the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.